Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
DISCOVERY BIOLOGYSupport For Drug Discovery
GMP/GLP compliant facility
2
GOOD MANUFACTURING PRACTICE GOOD LABORATORY PRACTICE
FIRST CERTIFICATE 2009 2011
CERTIFICATE ISSUED BY The Chief Pharmaceutical Inspectorate The Bureau for Chemical Substances
CERTIFICATE SCOPE• physical and chemical testing• biological testing in quality control of
medicines
• physical and chemical testing, mutagenicity studies
• chemical analyses and clinical chemistry testing
• cytotoxicity tests of chemical substances• bioanalysis and pharmacokinetic studies
Sp
eci
ali
zed
fu
nct
ion
al g
rou
p
Discovery Biology at Selvita – organizational chart
3
Assay Development& Screening Core Laboratory
Cell & Molecular BiologyCore laboratory
DISCOVERY BIOLOGY
Protein ChemistryCore Laboratory
Recombinant protein production
Protein characterization
Structural biology
Assay Development Unit
Screening & Compound Profiling Unit
Compound ManagementUnit
Biobanking / Bulk Tissue Culture Unit
Flow Cytometry Unit
Competencies
Areas of expertise
• Target validation studies
• In vitro Pharmacology
• Disease modelling
• Cancer Signaling
• Cancer Metabolism
• CNS disorders
• Inflammation
In vivo Preclinical PharmacologyUnit
Design and coordination of animal studies
Execution of the in vivo phase at partner’s
animal facility
Analysis
Sp
eci
ali
zed
fu
nct
ion
al g
rou
ps
Sp
eci
ali
zed
fu
nct
ion
al g
rou
ps
Pro
ject
-sp
eci
fic
gro
up
s
Integrated Drug Discovery Services
4
Target ID validation Hit ID H2L LOPreclinical
candidate selection
Validated HITs Optimized Hits/Leads Optimized Leads Preclinical Candidate
• Integrated Drug Discovery process at Selvita starts from hit
identification and lasts till preclinical candidate selection
• This process can be expanded with target validation accordingly
to the needs of a Partner
• Every step ends with reaching agreed and defined milestones
• Integrated process, according to Partner needs, can also be
custom composed of any blocks
• Selvita provides highly qualified team of scientists and managers
focused on the project plan and most advantageous solutions
H2L – hit to leadLO – lead optimization
• Selection and validation of in vitro cellular disease models
• Validation of target proteins of functional cellular assays
• Established viability/proliferation assays (MTS cell viability assay, BrdU incorporation assay)
• FACS cell cycle analysis
• Mitotic index for evaluation of proliferation levels
• Cell signaling profiling (ELISA, WB analysis)
• Established LDH – cell death assay
• FACS early apoptosis detection assay
• PARP cleavage for detection of apoptosis
• PARP activity colorimetric assays
• Caspase activity – apoptosis assay (labeled substrates)
• Clonogenic survival assay
• Senescence induction assay (in cells β-galactosidase activity assay)
• Combination index for evaluation of synergy
Selvita’s oncology platforms and molecular biology assays
5
CANCER METABOLISM STUDIES EPIGENETIC STUDIES
ENZYMATIC STUDIES
In vitro oncology – capabilities
• Functional assays in various monoaminergic
cloned receptors
• Availability of commercially available, stably
transfected cell lines
• In-house generation and validation of cloned
receptors cell lines
• cAMP-Glo assay, Calcium flux
Determination of the affinity of compounds for
receptor and the binding site density (Bmax)
of receptor families and their subtypes in different
tissue or samples
• Radioligand assays using [3H , 14C] ligands;
MicroBeta TriLux scintillation counter
(PerkinElmer)
• Fast development and optimization of
protocols
• Expertise in handling compounds with low
solubility in water and/or high lipophilicity
• Cytotoxicity: Neuronal cell death assays,
Neurotoxicity (MPP+, 6-OHDA, BSO), Excitotoxicity
(NMDA, glutamate)
▪ Gene and protein expression changes
(qPCR, WB, ELISA, Luminex, AlphaLISA, Flow
Cytometry)
▪ Production of inflammatory mediators
(microglia)
▪ Neurogenesis (BrdU)
▪ Tau hyperphosphorylation
Selvita’s CNS – in vitro pharmacodynamic studies
6
In vitro CNS – capabilities
GPCRs
CANCER METABOLISM PLATFORM EPIGENETIC PLATFORM
KINASE PLATFORM
Biophysical platform – hit ID/validation
7
PROTEIN FLUORESCENCE THERMAL SHIFT (FTS) ASSAY
Life Technologies QuantStudio 6 Real-Time PCR System with Protein
Thermal Shift technology – ΔTm calculation
MST – MICROSCALE THERMOPHORESIS
In solution analysis with Monolith NT.Automated (labelled vs. label-free) – Kd
SPR – SURFACE PLASMON RESONANCE
Immobilized protein label-free analysis with Biacore T200 (protein-protein
interactions and protein-small molecule interactions) – Kd, kinetic
parameters (kon, koff)
ITC – ISOTHERMAL CALORIMETRY
The system directly measures heat released or absorbed during
biochemical binding events, from which it calculates binding affinity (KD),
stoichiometry (n), enthalpy (ΔH), and entropy (ΔS).
RADIOLIGAND BINDING ASSAY3H-, 14C-Labelled
ELISA, AlphaLISA, TR-FRET/LanthaScreen, enzymatic assays etc.
Kit-based and custom assay development
QuantStudio 6 Flex Biacore T200
MicroCal PEAQ-ITC MST Monolith NT.Automated
HTS-mode available
Other assays
Cell metabolism – lipogenesis, glucose uptake etc.
Cell migration
Angiogenesis assays
Ligand binding, receptor activation, receptor binding
Assays specific for monoclonal antibodies – antibody dependent
cell-mediated cytotoxicity etc.
Enzymatic assays, protein-protein and drug-protein interaction
assays
Design of complementary in vitro studies required by the regulatory
authorities, under GMP certification.
8
Toxicology in vitro : Genotoxic assays
9
Selvita specializes in genotoxic characterization of chemical agents
Bacterial Reverse Mutation Test(AMES MPF™ Penta I, OECD 471)
The test is a standard bacterial assay which measures histidine reversion
(his- to his+) induced by chemicals causing base changes or frame shift
in the genome of this organism.
In Vitro Mammalian Cell Micronucleus Test (MNA, OECD 487)
This in vitro genetic toxicology assay is performed in the eukaryotic cell line
(CHO-K1) and measures formation of chromosomal changes following
DNA damage induced by the tested agents. This test is used for screening
purposes.
In Vitro Mammalian Cell Gene Mutation Tests Using
the Thymidine Kinase Gene (MLA, OECD 490)
This test is used to detect gene mutations induced by chemical substances
in vitro in mammalian cells. The test measures mutations in thymidine
kinase (TK), which enables to detect different spectra of genetic events. It
constitutes an excellent supplement for the Ames test. This test is used for
regulatory purposes.
Toxicology in vitro: other tests
10
Phototoxicity – mouse fibroblasts 3T3 NRU PT (OECD 432)
Skin irritation – Reconstructed Human Epidermis
– EpiDerm™ SIT (EPI-200) method (OECD 439)
Skin corrosion – Reconstructed Human Epidermis
– EpiDerm™ COR (EPI-200) method (OECD 431)
Eye irritation – Reconstructed human Cornea-like Epithelium (RhCE)
(OECD 492)
UV/IR Skin Irradiation, Photo Aging
– determination of anti-oxidant effects,
anti-inflammatory effects, photo-aging prevention
• Cells: primary human epidermal keratinocytes, primary human dermal
fibroblasts
• Measurements: ROS generation, DNA damage and repair,
Gene expression levels (eg. MMPs, Collagen), Cytokine detection using
ELISA/Luminex, Changes in protein phosphorylation (eg. MAPK, p38)
Development of custom, cell-based assays
– based on the literature data and Client’s requirements
ASSAY
DEVELOPMENT
& VALIDATION
Custom assay development service: biochemical and cell-based
12
Various detection modes
• absorbance
• fluorescence intensity
• fluorescence polarization
• time-resolved fluorescence (TRF) –
LANCE and DELFIA technologies
Wide range of available cellular models
case-by-case selection of suitable cellular model/s to investigate the biological
mechanism of interest (e.g. cancer cell panels of a specific type and/or with common
mutation patterns), in-house production and validation of recombinant cell lines
(if required)
Multi-factor design of assay development experiments
statistical parameters analysis to support a reliable and robust assay for routine use
• IC50/EC50
• mRSD (mean Relative Standard Deviation)
• S/N ratio
• LanthaScreen
• luminescence measurements
• AlphaLISA, AlphaScreen, AlphaPlex technologies
• SPR
• FACS
ADME/DMPK
In vitro ADME
14
Typical secondary ADME(T) tests
• Pharmacokinetic and bioavailability studies
• Metabolite profiling
• Cytochrome P450 inhibition (IC50)
• Genotoxicity and cytotoxicity
(performed by Cell Laboratory – MNA, MLA, Ames)
Typical primary ADME tests
• Solubility (HTS and thermodynamic)
• Lipophilicity (logD estimation at selected pH)
• Cytochrome P450 inhibition (screening)
• Permeability – PAMPA, Caco-2 (CacoReady kit)
• Plasma protein binding
(rapid equilibrium dialysis, ultrafiltration)
• Metabolic and plasma stability
Study type Mouse Rat
Pharmacokinetic
Pharmacodynamic
Pharmacodynamic
In vivo preclinical pharmacology
15
Design, coordination and analysis of animal studies
Selvita
• Design• Coordination• Model selection
Partner
• Execution of in vivo phase
• Equipped with modern
infrastructure
• Certified animal suppliers
• Own colonies
Selvita
• Analysis
• Conclusions
• Expertise and tools
for the analysis
Our team successfully designs, coordinates and analyzes data
from studies performed in animals
Selvita expertise and capabilities in:
Pharmacokinetics (in vivo) and analyticsSupportive toxicology testing
Pharmacodynamic studies for confirmation of potency and mechanism of action
In vivo preclinical pharmacology
16
Pharmacodynamic in vitro studies
Certified:
Signal transduction analysis
Binding studies and
affinity characterization
Biomarkers analysis in vitro and in vivo
Cytotoxicity and proliferation studies
Development and validation
of biochemical methods
Development and validation
of cell-based assays
Genotoxicity studies
Enzymatic activity testing
/company/selvita/
SelvitaKrakow
/Biotechnology-Company/Selvita-SA17
THANK YOU FOR ATTENTION!
Get in touch with us: [email protected]